Session Details

U046 Beyond the Bullae: What's New in Bullous Pemphigoid

Sun, Mar 21, 8:00 AM - 9:00 AM
1 CME Available Focus Session NEW

DESCRIPTION

Pemphigoid has experienced significant advancements in the understanding of pathophysiology, improved recognition of atypical clinical presentations and variants, and the emergence of new diagnostic techniques, and targeted treatments. This session will provide a high yield rapid fire dive into the more nuanced topics of nonbullous pemphigoid, drug-induced disease, advances in diagnostic testing options, and clinical mimics. Updates in immunopathology will be reviewed and connections drawn to new and emerging treatments. Approaches to managing the treatment refractory patient will be presented. Attendees will be empowered to recognize, diagnose, and treat the most difficult pemphigoid cases with confidence.

LEARNING OBJECTIVES

1.

Describe updates in the immunopathology underlying bullous pemphigoid and utilize this knowledge to prescribe up-to-date therapies for new onset and treatment refractory disease.

2.

Recognize classic and atypical clinical presentations of bullous pemphigoid and differentiate it from other inflammatory and bullous disorders.

3.

Distinguish bullous pemphigoid, drug-induced bullous pemphigoid, and mucous membrane pemphigoid with cutaneous involvement from one another and select laboratory diagnostic tests for their diagnosis.

SCHEDULE

8:00 AM

Beyond the antibodies: Updates on the pathophysiology

Donna Culton, MD, PhD, FAAD

8:10 AM

Beyond the bullae: Updates on clinical presenation

Prince Adotama, MD, FAAD

8:20 AM

Beyond the histology: Updates on the diagnostic tools

Brittney Schultz, MD, FAAD

8:30 AM

Beyond corticosteroids: Updates on targeted treatments

8:40 AM

Panel discussion and Q&A

DIRECTOR

Donna Culton, MD, PhD, FAAD

Donna Culton, MD, PhD, FAAD

University of North Carolina at Chapel Hill

SPEAKERS

Prince Adotama, MD, FAAD

Prince Adotama, MD, FAAD

Brittney Schultz, MD, FAAD

Brittney Schultz, MD, FAAD

DISCLOSURES

Prince Adotama, MD, FAAD

AbbVie – Advisory Board(Honoraria); arGEN-X – Advisory Board(Honoraria); Bristol-Myers Squibb – Consultant (1099 relationship)(Honoraria); Catalyst Medical Education LLC – Speaker(Honoraria); Dermsquared – Speaker/Faculty Education(Honoraria); Galderma – Consultant (1099 relationship)(Honoraria); Incyte – Advisory Board(Honoraria); Janssen Scientific Affairs, LLC – Advisory Board(Honoraria); Medscape – Speaker/Faculty Education(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Procter & Gamble Company – Advisory Board(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria); VeraDermics Inc. – Advisory Board(Honoraria);

Donna Culton, MD, PhD, FAAD

AbbVie – Advisory Board(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Almirall – Consultant (1099 relationship)(Fees); arGEN-X – Consultant(Fees); Eli Lilly and Company – Investigator(Salary); Enveda Biosciences – Consultant (1099 relationship)(Fees); Glycoera – Advisory Board(Fees); Incyte Corporation – Investigator(Salary); Janssen Global Services, LLC – Other(Residency/Fellowship Program Funding); Leo Pharma – Consultant (1099 relationship)(Fees), Investigator(Salary); Novartis – Advisory Board(Fees); Organon – Investigator(Salary); Pfizer Inc. – Investigator(Salary); Priovant Therapeutics – Consultant (1099 relationship)(Fees), Investigator(Salary); Regeneron – Consultant (1099 relationship)(Fees), Investigator(Salary), Speaker(Fees); Sanofi – Investigator(Salary); Sanofi Genzyme – Consultant (1099 relationship)(Fees); UpToDate – Other(Honoraria);

Brittney Schultz, MD, FAAD

Biocryst – Advisory Board(Honoraria); Hoffman-La Roche Ltd. – Investigator(No Compensation Received); Sanofi/Regeneron – Advisory Board(Honoraria); UCB – Investigator(No Compensation Received);